📌 Is ABBV a Buy right now?
According to Ultra Stock Analysis Pro, AbbVie Inc. (ABBV) is currently rated WAIT (Signal Strength: 0/7). The long-term fundamentals are strong (P/E: 98.8, Revenue Growth: +12.4%), while short-term technicals show a bearish trend (RSI: 43). Consider waiting for support confirmation near $212.46 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open ABBV Analysis ↗
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT rating to ABBV based on a confluence of 3 distinct factors:
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 56% of the time over a medium-term (months) hold period, with an average return of +5.7% per trade.
To assist with risk management, here are the three most probable paths for ABBV over the next trading week:
🟢 The Bull Case (Probability: 20%)
If ABBV reclaims the $212.46 resistance level (Bollinger Upper), algorithmic targets shift to $252.23. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 50%)
Failure to hold the $196.39 support zone (Bollinger Lower) triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $191.11 liquidity zone (-5.2% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 14 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $196.39 and $212.46 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $201.55 | Market Cap | $356.5B |
| Past Win Rate (Backtest) | 55.6% | Forward P/E | 12.4x |
| Past Total Return | +39.9% | Analyst Target | $252.23 |
| RSI / Trend Strength | 43 / 14 | Upside to Target | +25.1% |
| MACD Signal | Bearish | Revenue Growth | +12.4% |
| Profit Factor | 2.66 | Institutional Own. | 79.9% |
| Position Entry | 2026-04-29 @ $203.89 | Analyst Ratings | 21 Buy / 9 Hold / 1 Sell |
| Open Position Past P&L | -1.1% |
MAINTAIN POSITION - Current position showing -1.1% unrealized gain. Use intelligent stop loss strategy below.
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit (tighter as profit grows).
Fixed 2.0x ATR Stop Loss
Entry: $203.89 on 2026-04-29
Confluence: 5.0
Stop Loss: $190.97
Backtest Results (Since 2018):
Past Win Rate
56%
Past Total Return
+39.9%
Max Drawdown
-16.1%
Avg Trade
+5.7%
Trades
18
Adaptive ATR Stop Loss (1.0-2.75x)
Entry: $203.89 on 2026-04-29
Confluence: 5.0
Stop Loss: $193.62
Backtest Results (Since 2018):
Past Win Rate
56%
Past Total Return
+39.9%
Max Drawdown
-16.1%
Avg Trade
+5.7%
Trades
18
Current Price
$201.55
Buy Stop Loss
$190.97
Distance: 5%
Conservative 2.0x
Position Stop Loss
$188.33
Distance: 7%
Hybrid 2.50x
ATR 14 Day
$5.29
Volatility
ADX Strength
14.5
Weak/No Trend
Position down -1% - Wider stops for recovery
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
| Indicator | Value | Signal |
|---|---|---|
| EMA 20 | $205.08 | Bearish |
| EMA 50 | $209.41 | Bearish |
| RSI (14) | 43.2 | Neutral range |
| Trend Strength (ADX) | 14.5 | Weak/No trend (<20) |
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| Guggenheim | REITERATED | Buy → Buy | May 01, 2026 |
| Cantor Fitzgerald | REITERATED | Overweight → Overweight | Apr 30, 2026 |
| Canaccord Genuity | INITIATED | Buy | Apr 21, 2026 |
| RBC Capital | INITIATED | Outperform | Feb 25, 2026 |
| Barclays | INITIATED | Overweight | Feb 20, 2026 |
| Average Target: | $252.23 | High Target: | $328.00 |
| Current Price: | $201.55 | Low Target: | $184.00 |
| Upside to Average: | +25.1% | Number of Analysts: | 30 |
Based on backtest performance (Win Rate: 55.6%, Avg Return: +5.7%) and analyst consensus (Target: $252.23, +25.1% upside), an OVERWEIGHT exposure may be considered. Risk/Reward ratio of 1.68:1 suggests moderate risk-adjusted returns. Current open position shows -1.1% unrealized gain.
AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 12.4x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 31.6% shows strong profitability.
Fundamental Outlook: Moderate Growth - Monitoring profitability amid revenue expansion
Overall Score: 4.1/10 - Bullish
AbbVie (NYSE:ABBV) told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-...
IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results....
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named ...
Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD) and Vanguard High Dividend Yield ETF (NYSEARCA: VYM) sit on most income investors’ shortlists. Both e...
Q1 earnings show this Dividend King still looks built for the long term....
The news sentiment is strongly bullish, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.
| Metric | Value |
|---|---|
| Market Cap | $356.5B |
| P/E Ratio (Forward) | 12.4 |
| EPS (Forward) | $16.21 |
| Dividend Yield | 3.43% |
| 52-Week Range | $176.57 - $244.81 |
| Beta | 0.30 |
| Avg Volume | 6.9M |
Comprehensive Technical Data for Quantitative Analysis
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Close Price | $201.55 | Volume | 4.9M |
| EMA 20 | $205.08 | EMA 50 | $209.41 |
| EMA 200 | $210.26 | Current Price | $201.55 |
| RSI (14) | 43.18 | MACD | -1.666 |
| MACD Signal | -2.062 | MACD Histogram | 0.396 |
| Trend Strength (ADX) | 14.49 | Volatility (ATR 14) | $5.29 |
| Bollinger Upper | $212.46 | Bollinger Lower | $196.39 |
| Stochastic %K | 51.19 | Stochastic %D | 57.90 |
| VWAP | $201.32 | Bollinger Middle | $204.43 |
| Confluence Score | 0/7 | Trade Signal | NONE |
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $356.5B | Revenue | $62.8B |
| Forward P/E | 12.4 | Revenue Growth | +12.4% |
| Trailing P/E | 98.8 | Gross Margin | 72.0% |
| Price/Sales | 5.67 | Operating Margin | 31.6% |
| Price/Book | -108.95 | Profit Margin | 5.8% |
| PEG Ratio | 0.56 | ROE | 0.0% |
| Enterprise Value | $419.6B | Free Cash Flow | $0.0B |
Comprehensive Trading Performance and Position Details
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-04-29 | $203.89 | -1.15% | $192.56 |
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2023-06-01 | 2023-08-16 | $119.84 | $137.61 | +14.83% | Win |
| 2023-09-14 | 2023-10-05 | $139.51 | $133.89 | -4.03% | Loss |
| 2023-10-19 | 2023-11-14 | $133.46 | $126.61 | -5.13% | Loss |
| 2023-12-11 | 2024-04-16 | $138.70 | $151.89 | +9.51% | Win |
| 2024-04-26 | 2024-07-01 | $149.17 | $159.21 | +6.73% | Win |
| 2024-07-25 | 2024-11-13 | $171.80 | $161.94 | -5.74% | Loss |
| 2025-01-22 | 2025-04-10 | $162.36 | $167.16 | +2.96% | Win |
| 2025-09-11 | 2025-09-22 | $215.11 | $217.43 | +1.08% | Win |
| 2025-09-30 | 2025-11-05 | $226.17 | $213.27 | -5.70% | Loss |
| 2025-11-12 | 2026-01-14 | $229.46 | $218.31 | -4.86% | Loss |
Summary: 18 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-05-08. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.
Report Generated: May 09, 2026 at 12:52 PM
Ultra Stock Analysis Pro - Comprehensive Technical & Fundamental Analysis